Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Granulocyte-macrophage colony-stimulating factor is a key mediator in inflammatory and arthritic pain.

Cook AD, Pobjoy J, Sarros S, Steidl S, Dürr M, Lacey DC, Hamilton JA.

Ann Rheum Dis. 2013 Feb;72(2):265-70. doi: 10.1136/annrheumdis-2012-201703. Epub 2012 Jul 24.

PMID:
22833372
2.

Regulation of systemic and local myeloid cell subpopulations by bone marrow cell-derived granulocyte-macrophage colony-stimulating factor in experimental inflammatory arthritis.

Cook AD, Turner AL, Braine EL, Pobjoy J, Lenzo JC, Hamilton JA.

Arthritis Rheum. 2011 Aug;63(8):2340-51. doi: 10.1002/art.30354.

3.

Granulocyte-macrophage colony-stimulating factor is a key mediator in experimental osteoarthritis pain and disease development.

Cook AD, Pobjoy J, Steidl S, Dürr M, Braine EL, Turner AL, Lacey DC, Hamilton JA.

Arthritis Res Ther. 2012 Sep 20;14(5):R199. doi: 10.1186/ar4037.

4.

Multi-response model for rheumatoid arthritis based on delay differential equations in collagen-induced arthritic mice treated with an anti-GM-CSF antibody.

Koch G, Wagner T, Plater-Zyberk C, Lahu G, Schropp J.

J Pharmacokinet Pharmacodyn. 2012 Feb;39(1):55-65. doi: 10.1007/s10928-011-9230-4. Epub 2011 Dec 23.

PMID:
22193331
5.
6.
8.

Granulocyte-macrophage colony stimulating factor exacerbates collagen induced arthritis in mice.

Campbell IK, Bendele A, Smith DA, Hamilton JA.

Ann Rheum Dis. 1997 Jun;56(6):364-8.

9.

Combined blockade of granulocyte-macrophage colony stimulating factor and interleukin 17 pathways potently suppresses chronic destructive arthritis in a tumour necrosis factor alpha-independent mouse model.

Plater-Zyberk C, Joosten LA, Helsen MM, Koenders MI, Baeuerle PA, van den Berg WB.

Ann Rheum Dis. 2009 May;68(5):721-8. doi: 10.1136/ard.2007.085431. Epub 2008 May 21.

PMID:
18495731
11.

Protection from collagen-induced arthritis in granulocyte-macrophage colony-stimulating factor-deficient mice.

Campbell IK, Rich MJ, Bischof RJ, Dunn AR, Grail D, Hamilton JA.

J Immunol. 1998 Oct 1;161(7):3639-44.

12.
13.

Differentiation of inflammatory dendritic cells is mediated by NF-κB1-dependent GM-CSF production in CD4 T cells.

Campbell IK, van Nieuwenhuijze A, Segura E, O'Donnell K, Coghill E, Hommel M, Gerondakis S, Villadangos JA, Wicks IP.

J Immunol. 2011 May 1;186(9):5468-77. doi: 10.4049/jimmunol.1002923. Epub 2011 Mar 18.

14.
15.

GM-CSF neutralisation suppresses inflammation and protects cartilage in acute streptococcal cell wall arthritis of mice.

Plater-Zyberk C, Joosten LA, Helsen MM, Hepp J, Baeuerle PA, van den Berg WB.

Ann Rheum Dis. 2007 Apr;66(4):452-7. Epub 2006 Oct 4.

16.

GM-CSF as a target in inflammatory/autoimmune disease: current evidence and future therapeutic potential.

Hamilton JA.

Expert Rev Clin Immunol. 2015 Apr;11(4):457-65. doi: 10.1586/1744666X.2015.1024110. Epub 2015 Mar 8. Review.

PMID:
25748625
19.

Organ-specific autoimmunity in granulocyte macrophage-colony stimulating factor (GM-CSF) deficient mice.

Alderuccio F, Biondo M, Toh BH.

Autoimmunity. 2002 Feb;35(1):67-73.

PMID:
11908710
20.

GM-CSF as a therapeutic target in inflammatory diseases.

van Nieuwenhuijze A, Koenders M, Roeleveld D, Sleeman MA, van den Berg W, Wicks IP.

Mol Immunol. 2013 Dec;56(4):675-82. doi: 10.1016/j.molimm.2013.05.002. Epub 2013 Aug 8. Review.

PMID:
23933508

Supplemental Content

Support Center